ASAS/EULAR recommendations for the management of ankylosing spondylitis: The patient version

Annals of the Rheumatic Diseases

Volumn 68, Issue 9, 2009, Pages 1381-1386

  Kiltz, U ^a   Van Der Heijde, D ^b   Mielants, H ^c   Feldtkeller, E ^d   Braun, J ^a  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d Ankylosing Spondylitis International Federation   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYLOSING SPONDYLITIS; ARTICLE; CONSENSUS DEVELOPMENT; EVALUATION; LANGUAGE; MEDICAL SOCIETY; MEDICAL SPECIALIST; PATIENT EDUCATION; PRIORITY JOURNAL; PUBLICATION;

ADULT; AGED; COMPREHENSION; FEMALE; HUMANS; INTERNATIONAL COOPERATION; LANGUAGE; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PATIENT PARTICIPATION; PRACTICE GUIDELINES AS TOPIC; SPONDYLITIS, ANKYLOSING;

EID: 69949190443     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.096073     Document Type: Article

References (18)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-1390
2. Braun J, van der Heijde D. Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin Rheumatol 2002;16:573-604.
3. Henderson C, Davis JC. Drug Insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis. Nat Clin Pract Rheumatol 2006;2:211-218
4. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis Jr JC, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-452
5. Braun J, Pham T, Sieper J, Davis J, van der Linden SJ, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-824 (Pubitemid 37026490)
6. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D, for the ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-320
7. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/ EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-432
8. Maksymowych WP, Imman RD, Gladman D, Thomson G, Stone M, Karsh J, et al. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol 2003;30:1356-1363 (Pubitemid 36666368)
9. Maksymowych W, Gladman D, Rahman P, Boonen A, Bykerk A, Choquette D, et al. The Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis: A National Multidisciplinary Stakeholder Project. J Rheumatol 2007;34:2273-2284 (Pubitemid 350076891)
10. The AGREE Collaboration. Appraisal of guidelines for research and evaluation (AGREE) instrument. September 2001. Available from http://www.agreecollaboration. org (accessed 14 June 2009).
11. Kiltz U, Feldtkeller E, Braun J. Patient evaluation of the German version of the ASAS/ EULAR recommendations for the management of ankylosing spondylitis. Z Rheumatol 2008;67:694-700.
12. Dougados M, Betteridge N, Burmester GR, Euller-Ziegler L, Guillemin F, Hirvonen J, et al. EULAR standardized operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-1176 (Pubitemid 39120376)
13. Gossec L, Dougados M, Phillips C, Hammoudeh M, de Vlam K, Pavelka K, et al. Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. Ann Rheum Dis 2007;67:782-788 (Pubitemid 351829378)
14. Braun J, Zochling J, Märker-Hermann E, Stucki G, Böhm H, Rudwaleit M, et al. Recommendations for the management of ankylosing spondylitis after ASAS/ EULAR. Evaluation in the German language area. Z Rheumatol 2006;65:728-742
15. Simon JA, Burgos-Vargas R. Agreement of Mexican rheumatologists with the ASessment in Ankylosing Spondylitis International Working Group and the European League Against Rheumatism recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:1535-1536 (Pubitemid 44629141)
16. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004;8:iii-iv, 1-72. (Pubitemid 38279464)
17. WHO. International classification of functioning, disability and health. Geneva: World Health Organization, 2001. Available at http://www.who.int/ classifications/icf/en/ (accessed 14 Jun 2009).
18. Van Echteld I, Cieza A, Boonen A, Stucki G, Zochling J, Braun J, et al. Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. J Rheumatol 2006;33:2475-2483 (Pubitemid 46067829)